What is the risk-to-benefit ratio of ACE-Is or ARBs when used in CKD patients?
The use of ACE-Is or ARBs may not have the same risk-to-benefit ratio in CKD patients as in non-CKD populations, as CKD patients are at higher risk of side effects, particularly hyperkalemia and reduction in GFR. In reviewing studies specifically involving patients with CKD, no important differences in the effect of ARBs on BP or side effects were found, however it is not possible to make any recommendations for CKD patients in particular since the data are largely from studies of non-CKD patients.